Incyte Excites, ADMP Entitled To Patent, BSX Gets Two Thumbs Up, ORMP On Watch

(RTTNews) - Adamis Pharmaceuticals Corp. (ADMP) has been issued a notice of allowance by the U.S. Patent Office patent for the company's prostate cancer drug candidate APC-100, which is a part of a phase 1/2a clinical study.

ADMP.OB closed Wednesday's trading at $0.43, unchanged from the previous day's close.

Biologix Hair Inc. (BLGX) is set to implement a 1 for 2 reverse split on or about September 3, 2013. In order to maximize management efficiency and cost effectiveness during its development stage, Biologix will no longer be filing annual and quarterly reports with the SEC under provisions of filing Form 15.

BLGX.OB closed Wednesday's trading at $0.75.

BioReference Laboratories Inc.'s (BRLI) wholly-owned clinical diagnostic sequencing laboratory GeneDx is all set to acquire Edge BioSystems CLIA laboratory business and related assets.

The company said that Dean Gaalaas, CEO of EdgeBio, will assume the position of COO at GeneDx.

BRLI gained 2.10% on Wednesday to close at $26.78.

Boston Scientific Corp. (BSX) has strengthened its portfolio of next generation electrophysiology tools designed to redefine ablation technology by two more products. The company's IntellaTip MiFi XP catheter has been approved by FDA and its Zurpaz 8.5F steerable sheath has received 510(k) clearance.

BSX closed Wednesday's trading 0.82% higher at $11.10.

CombiMatrix Corp. (CBMX) has regained compliance with the Nasdaq minimum stockholders' equity requirement of $2.5 million. As of June 30, 2013, stockholders' equity of the company was $5.7 million.

CBMX closed Wednesday's trading at $2.81, down 3.10%.

DelMar Pharmaceuticals Inc. (DMPI.OB) has been allowed by FDA to accelerate the dose-escalation of its ongoing phase I/II of VAL-083 in refractory glioblastoma multiforme patients. Accordingly, the trial will skip two interim doses. The company plans to complete the dose-escalation during 2013 and advance into registration-directed trials in 2014.

DMPI.OB closed Wednesday's trading at $1.07, down 2.73%.

Incyte Corp. (INCY) rose as much as 38 percent on Wednesday to touch a high of $37.46 following news of its cancer drug Ruxolitinib achieving a demonstrable survival benefit in a well-defined group of patients with refractory metastatic pancreatic cancer who can be identified without the development of a companion diagnostic test in a phase II trial.

The full results of the trial, dubbed RECAP, are expected to be presented at a future scientific meeting.

Ruxolitinib, under brand name Jakafi, is already approved for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The drug garnered sales of $136 million in 2012.

Oramed Pharmaceuticals Inc. (ORMP) has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.

ORMP closed Wednesday's trading at $7.41, up 1.51%.